The relationship between benign breast disease and use of oral contraceptives was analyzed in a case-control study conducted in Milan with 288 cases of clinically relevant and histologically confirmed benign breast disease and 285 age-matched controls with a spectrum of acute conditions apparently unrelated to use of oral contraceptives. Compared to the risk for women who had never used oral contraceptives, the relative risk for users was 1.0 (95% confidence interval: 0.6 to 1.5). There was no significant association with duration of use; however, a significantly lower relative risk was found in women using oral contraceptives during the year before breast biopsy (relative risk: 0.4; 95% confidence interval: 0.2 to 0.8). The protection in current users increased with increasing duration of use. In spite of this finding, the overall results of the present study do not support the hypothesis that oral contraceptive use protects against development of histologically confirmed and clinically relevant benign breast disease.

Oral contraceptives and benign breast disease: a case-control study / S. Franceschi, C. La Vecchia, F. Parazzini, M. Fasoli, M. Regallo, A. Decarli, G. Gallus, G. Tognoni. - In: AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY. - ISSN 0002-9378. - 149:6(1984 Jul 15), pp. 602-606. [10.1016/0002-9378(84)90242-4]

Oral contraceptives and benign breast disease: a case-control study

C. La Vecchia;F. Parazzini;A. Decarli;
1984

Abstract

The relationship between benign breast disease and use of oral contraceptives was analyzed in a case-control study conducted in Milan with 288 cases of clinically relevant and histologically confirmed benign breast disease and 285 age-matched controls with a spectrum of acute conditions apparently unrelated to use of oral contraceptives. Compared to the risk for women who had never used oral contraceptives, the relative risk for users was 1.0 (95% confidence interval: 0.6 to 1.5). There was no significant association with duration of use; however, a significantly lower relative risk was found in women using oral contraceptives during the year before breast biopsy (relative risk: 0.4; 95% confidence interval: 0.2 to 0.8). The protection in current users increased with increasing duration of use. In spite of this finding, the overall results of the present study do not support the hypothesis that oral contraceptive use protects against development of histologically confirmed and clinically relevant benign breast disease.
Contraception Continuation; Contraceptive Agents; Research Methodology; Humans; Physiology; Contraceptives, Oral; Contraceptive Agents, Female; Europe; Developed Countries; Population At Risk; Italy; Southern Europe; Adult; Data Collection; Diseases; Mammary Gland Effects; Family Planning; Adolescent; Time Factors; Contraceptive Methods--beneficial effects; Questionnaires; Fibrocystic Breast Disease; Oral Contraceptives--beneficial effects; Breast Neoplasms; Risk; Contraception; Mediterranean Countries; Middle Aged; Female; Biology
Settore MED/01 - Statistica Medica
Settore MED/40 - Ginecologia e Ostetricia
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/185044
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 10
  • ???jsp.display-item.citation.isi??? ND
social impact